| Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis K Harding, O Williams, M Willis, J Hrastelj, A Rimmer, F Joseph, ... JAMA neurology 76 (5), 536-541, 2019 | 328 | 2019 |
| Ultra-high-field imaging distinguishes MS lesions from asymptomatic white matter lesions EC Tallantyre, JE Dixon, I Donaldson, T Owens, PS Morgan, PG Morris, ... Neurology 76 (6), 534-539, 2011 | 241 | 2011 |
| Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis EC Tallantyre, L Bø, O Al-Rawashdeh, T Owens, CH Polman, JS Lowe, ... Multiple Sclerosis Journal 16 (4), 406-411, 2010 | 215 | 2010 |
| Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial RAS Salman, MS Dennis, PAG Sandercock, CLM Sudlow, JM Wardlaw, ... The Lancet 393 (10191), 2613-2623, 2019 | 197 | 2019 |
| A comparison of 3T and 7T in the detection of small parenchymal veins within MS lesions EC Tallantyre, PS Morgan, JE Dixon, A Al-Radaideh, MJ Brookes, ... Investigative radiology 44 (9), 491-494, 2009 | 193 | 2009 |
| Demonstrating the perivascular distribution of MS lesions in vivo with 7-Tesla MRI EC Tallantyre, MJ Brookes, JE Dixon, PS Morgan, N Evangelou, ... Neurology 70 (22), 2076-2078, 2008 | 187 | 2008 |
| Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis D Ontaneda, E Tallantyre, T Kalincik, SM Planchon, N Evangelou The Lancet Neurology 18 (10), 973-980, 2019 | 177 | 2019 |
| COVID‐19 vaccine response in people with multiple sclerosis EC Tallantyre, N Vickaryous, V Anderson, AN Asardag, D Baker, ... Annals of neurology 91 (1), 89-100, 2022 | 165 | 2022 |
| 3 Tesla and 7 Tesla MRI of multiple sclerosis cortical lesions EC Tallantyre, PS Morgan, JE Dixon, A Al‐Radaideh, MJ Brookes, ... Journal of Magnetic resonance imaging 32 (4), 971-977, 2010 | 153 | 2010 |
| Imaging central veins in brain lesions with 3-T T2*-weighted magnetic resonance imaging differentiates multiple sclerosis from microangiopathic brain lesions N Mistry, R Abdel-Fahim, A Samaraweera, O Mougin, E Tallantyre, ... Multiple Sclerosis Journal 22 (10), 1289-1296, 2016 | 140 | 2016 |
| Greater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive disease EC Tallantyre, L Bø, O Al-Rawashdeh, T Owens, CH Polman, J Lowe, ... Brain 132 (5), 1190-1199, 2009 | 127 | 2009 |
| Central veins in brain lesions visualized with high-field magnetic resonance imaging: a pathologically specific diagnostic biomarker for inflammatory demyelination in the brain N Mistry, J Dixon, E Tallantyre, C Tench, R Abdel-Fahim, T Jaspan, ... JAMA neurology 70 (5), 623-628, 2013 | 108 | 2013 |
| Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART … RAS Salman, DP Minks, D Mitra, MA Rodrigues, P Bhatnagar, ... The Lancet Neurology 18 (7), 643-652, 2019 | 98 | 2019 |
| Rituximab in neurological disease: principles, evidence and practice DH Whittam, EC Tallantyre, S Jolles, S Huda, RJ Moots, HJ Kim, ... Practical Neurology 19 (1), 5-20, 2019 | 96 | 2019 |
| Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation EC Tallantyre, DH Whittam, S Jolles, D Paling, C Constantinesecu, ... Journal of Neurology 265, 1115-1122, 2018 | 89 | 2018 |
| Spotlight on teriflunomide E Tallantyre, N Evangelou, CS Constantinescu The International MS Journal 15 (2), 62-69, 2008 | 83 | 2008 |
| Neurological updates: neurological complications of CAR-T therapy EC Tallantyre, NA Evans, J Parry-Jones, MPG Morgan, CH Jones, ... Journal of Neurology 268 (4), 1544-1554, 2021 | 64 | 2021 |
| Comparing MRI metrics to quantify white matter microstructural damage in multiple sclerosis I Lipp, DK Jones, S Bells, E Sgarlata, C Foster, R Stickland, AE Davidson, ... Human brain mapping 40 (10), 2917-2932, 2019 | 59 | 2019 |
| An observational study of alemtuzumab following fingolimod for multiple sclerosis M Willis, O Pearson, Z Illes, T Sejbaek, C Nielsen, M Duddy, K Petheram, ... Neurology: Neuroimmunology & Neuroinflammation 4 (2), e320, 2017 | 59 | 2017 |
| COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies A Garjani, RM Middleton, R Hunter, KA Tuite-Dalton, A Coles, R Dobson, ... Multiple sclerosis and related disorders 52, 102939, 2021 | 57 | 2021 |